ArticleFrontiers in endocrinology2025
Positive correlations between TyG and TyG-BMI indices and the risk of NAFLD and degree of liver fibrosis in patients undergoing PCI.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aim to investigate the association between TyG(Triglyceride-Glucose index) and TyG-BMI(Triglyceride-Glucose-Body Mass Index) indices and the risk of non-alcoholic fatty liver disease (NAFLD) in patients undergoing percutaneous coronary intervention (PCI), an area where their predictive value is currently unclear, despite their established link to insulin resistance, metabolic syndrome, and cardiovascular disease. Methods: In this cross-sectional study, 776 patients who underwent coronary angiography and PCI were categorized into NAFLD+PCI and PCI groups based on abdominal ultrasound. They were further classified by TyG and TyG-BMI indices. Continuous variables were compared using ANOVA, Wilcoxon-Mann-Whitney, or t-tests, while categorical variables were analyzed with χ² or Fisher exact tests. Logistic regression identified independent factors for NAFLD in PCI patients. ROC curves evaluated the predictive efficacy of TyG and TyG-BMI for NAFLD. Linear correlation and multiple linear regression assessed relationships among NAFLD fibrosis score (NFS), TyG, and TyG-BMI. Results: Among 776 patients, NAFLD was detected in 305. After adjusting for age, smoking, hypertension, diabetes, sex, and cardiovascular disease, multivariate logistic regression showed the TyG index was a significant risk factor for NAFLD in PCI patients (OR = 2.04; 95% CI, 1.62-2.55; P < 0.001). Similarly, the TyG-BMI index, total cholesterol, triglycerides, LDL cholesterol, fasting blood glucose, and BMI were associated with increased NAFLD risk. Each unit increase in the TyG index raised the NAFLD risk by 2.63-fold (OR = 2.63; 95% CI, 1.78-3.8; P<0.001), and each unit increase in the TyG-BMI index by 3.80-fold (OR = 3.80; 95% CI, 2.55-5.68; P < 0.001). Multivariate linear regression indicated that in the PCI-NAFLD group, each unit increase in the TyG index increased the NFS value by 0.247 (β = 0.247; 95% CI, 0.19-0.45; P < 0.001), and each unit increase in the TyG-BMI index increased the NFS value by 0.344 (β = 0.344; 95% CI, 0.28-0.59; P < 0.001). Conclusions: The TyG index and TyG-BMI were positively associated with the risk of NAFLD in patients treated with PCI, reflecting the severity of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.